Dostinex (also known as cabergoline) is manufactured by Pfizer to treat hyperprolactinemia, a hormone and blood disorder, and Parkinson’s disease. In December 1996, however, the Food and Drug Administration (“FDA”) approved Dostinex to treat only hyperprolactinemia, although many doctors in the United States prescribe Dostinex to patients with Parkinson’s disease. Unfortunately, Dostinex use by patients with Parkinson’s disease may cause severe and even fatal heart valve damage.

Dostinex Lawsuits: Manufacturing an Unsafe Product

Injured victims can file a Dostinex lawsuit against Pfizer for manufacturing an unsafe drug. Pfizer manufactured Dostinex to treat Parkinson’s disease and received approval from European health authorities. Although the FDA did not approve Dostinex to treat Parkinson’s disease, Dostinex lawsuits allege that Pfizer knew or should have known that doctors would prescribe Dostinex to Parkinson’s patients in the United States.

Dostinex lawsuits note that many studies link Dostinex use to severe heart valve damage including:

  • An Italian study that concluded that 29% of patients using Dostinex developed moderate to severe heart valve damage
  • A German study that revealed that Dostinex users were five times more likely to develop heart valve damage than patients not taking Dostinex
  • A British study that determined that 19% of patients taking Dostinex developed heart valve damage, which was five to seven percent more than patients who did not take Dostinex

Dostinex Lawsuits: Failure to Warn

Dostinex lawsuits allege that Pfizer should have warned users about potential Dostinex side effects, especially Parkinson’s patients. The lawsuits note that drug manufacturers are responsible to warn users about dangerous side effects. The lawsuit complaints allege that Pfizer knew that Dostinex use may cause serious and even fatal side effects and that it failed to adequately warn the public.

Dostinex Lawsuits: Dostinex Remains on the Market

Dostinex lawsuits claim that Pfizer should discontinue manufacturing Dostinex. The lawsuits highlight that Bryan Roth, the National Institute of Mental Health’s drug screening program director, found it suspect that initial clinical tests on Dostinex did not reveal the increased heart valve damage risk. Roth called for doctors to stop prescribing Dostinex and recommended that patients be examined for heart valve damage. Dostinex lawsuits further assert that Pfizer should have pulled Dostinex off the market.

Filing Dostinex Lawsuits

If you or a loved one has been injured from Dostinex use, or would like more information on Dostinex lawsuits, please contact us today as you may be able to file a Dostinex lawsuit. Our Dostinex lawyers can assist in filing a potential lawsuit to recover compensation for:

  • medical bills
  • pain and suffering
  • lost work
  • mental anguish

Published November 17, 2011 by